Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Selinexor alone and in combination with JAK inhibitors suppresses pro-inflammatory cytokine secretion from primary myelofibrosis cells ex vivo

View Full Paper
Ask AI
Bookmark
Share

Authors

TKTrinayan KashyapRRRaajit K. RampalPVPankit Vachhani

Discussion

Loading...

Member takes

Overview

Ex vivo treatment with selinexor and JAK inhibitors reduces IL-6 and TNFα in JAKi-naïve myelofibrosis patients, indicating potential therapeutic benefits.

Key Points

  • The research aims to evaluate the effects of selinexor and JAK inhibitors on pro-inflammatory cytokines in myelofibrosis patients.
  • Assessed NF-κB activity in myelofibrosis cells treated with selinexor and JAK inhibitors.
  • Used PBMCs from JAKi-naïve myelofibrosis patients for ex vivo analysis.
  • Quantified IL-6 and TNFα levels post-treatment with immunoassays.
  • Selinexor significantly reduced NF-κB activity regardless of mutation status.
  • Ex vivo treatments showed varying degrees of inhibition of IL-6 and TNFα secretion.
  • Combination treatment of selinexor with ruxolitinib enhanced cytokine suppression compared to single-agent treatments.

Cite This Study

Kashyap et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5a6https://doi.org/10.1182/blood-2025-5537
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1XPO1 inhibition by selinexor blocks nucleo-cytoplasmic trafficking of multiple members of the NF-kb family in MPN cell lines and primary myelofibrosis cells2025 · 1 citations
  2. 2Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription ( JAK / STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways2026
  3. 3Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics2025
  4. 4Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.2024 · 2 citations
  5. 5Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.2024 · 1 citations